The Canadian Journal of Psychiatry · 1999 · 44 citations · 12 references
MedicinePharmacotherapyPsychiatryClinical PharmacologyPsychiatric PharmacotherapyPsychopharmacologyAcute Psychosis ManagementAntipsychotic PharmacologyAntipsychotic PharmacotherapyAntipsychotic TherapyDose OptimizationPsychosis AssessmentAntipsychotic Dose OptimizationClinical Dose OptimizationExtrapyramidal SignsFirst-episode Psychosis TreatmentHaloperidol PharmacologyNegative Syndrome ScaleOptimal Dose SelectionPsychosis Pharmacotherapy
OBJECTIVE: To determine optimal doses of haloperidol for the treatment of a first episode of psychosis. METHOD: A 4-week prospective controlled clinical trial with "optimal dose" defined as the dose at which either of the following occurs: 1) significant improvement, defined as a 15% or greater decrease in scores on the Positive And Negative Syndrome Scale (PANSS), or 2) the onset of extrapyramidal symptoms. Beginning with 2 mg daily, haloperidol was increased weekly to 5 mg, 10 mg, and finally 20 mg daily until either 1) or 2) occurred. RESULTS: Optimal doses for the 36 subjects were 2 mg daily for 15 subjects, 5 mg daily for 11, 10 mg daily for 7, and 20 mg daily for 3. On average, subjects whose optimal dose was 2 mg daily showed the greatest improvement. Among the 27 subjects evidencing clinical response to treatment, 20 had plasma haloperidol levels below 5 ng/ml. CONCLUSION: Many people suffering a first psychotic episode respond to haloperidol doses well below levels in common use.
12
The Structured Clinical Interview for DSM-III-R (SCID)
Janet B. W. Williams · Archives of General Psychiatry · 1992 · 1.6K citations
Education, Psychiatry, Psychology +14
Best Estimate of Lifetime Psychiatric Diagnosis
James F. Leckman · Archives of General Psychiatry · 1982 · 1.4K citations